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Poster Session I S247were detected not by G-banding but by mRT-PCR in 20 patients
and unfavorable aberrations including t(9;22), t(11;19), t(4;11), and
t(1;19) were detected by mRT-PCR, not by G-banding, in 14
patients. On the other hand, mRT-PCR could not detect various
complexities in 55 patients. Unfavorable aberrations detected by
G-banding, not by mRT-PCR, showed relatively poor survival out-
comes in chemotherapy group and transplant group (p 5 0.053 and
0.004, respectively). Favorable aberrations detected by mRT-PCR
should be considered as good prognosis even G-banding technique
did not detect any aberrations (p 5 0.023). However, the difference
has abolished by autologous or allogeneic hematopoietic stem cell
transplantation. mRT-PCR technique can be a complementary
diagnostic tool of acute leukemia when combined with conventional
cytogenetics and the molecular result is predictable for the prognosis
and the resultant survival.254
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Background: Children with high-risk AML (induction failure [IF],
re-induction failure after relapse [RIF], refractory relapse [RR],
3rd complete remission [CR3]) have dismal outcomes (overall sur-
vival [OS] 10-20%) (Michallet et al. BMT, 2000; Shenoy et al.
BMT 2008). Over 80% of AML patients express CD33. Gemtuzu-
mab Ozogamicin (GO) alone and in combination with chemother-
apy is safe and active in childhood AML.
Objectives: To determine the safety, maximum tolerated dose
(MTD) and efficacy of GO in combination with busulfan/cyclophos-
phamide (BU/CY) followed by AlloSCT.
Methods:GOwas administered on Day -14 at doses of 3.0, 4.5, 6.0,
7.5 mg/m2, and BU Days -7, -6, -5, -4 at doses of 12.8-16.0 mg/kg,
and CY Days -3, and -2 at doses of 60 mg/kg followed by allogeneic
hematopoietic stem cell transplantation (AlloSCT). GVHDprophy-
laxis consisted of tacrolimus/mycophenolate mofetil.
Results: Twelve patients: 5-IF, 2-RIF, 4-RR,1-CR3; median age:
3yrs (range 1-17) withmedian follow-up of 1379d (939-2305) in alive
patients. Nine UCBT (3 each HLA 6/6-, 5/6-, 4/6-match), 2 MUD
(10/10) and 1 MSD. 3 patients each at GO doses of 3.0, 4.5, 6.0, or
7.5 mg/m2. No dose-limiting toxicities secondary to GO were ob-
served. Day 100 transplant related mortality was 0%. Neutrophil
and platelet engraftment was observed in 92% and 75% of patients
at median day 22 (12-40) and 42 (21-164), respectively. Median
day 130 donor chimerism was 99% (85-100%). The probability of
grade II-IV aGVHD was 42% while cGVHD was 28%. Seven of
12 patients relapsed, 5 have died from progressive disease, 6 year
event-free survival (EFS) and OS was 33% (CI9510-58%) and 50%
(CI9521-73%), respectively.
Conclusion: GO combined with a MAC regimen followed by Al-
loSCT is well-tolerated in children with high-risk AML and is asso-
ciated with improved EFS and OS compared to historical controls.
The safe and tolerable dose of GO at 7.5mg/m2 will be studied in
a phase II clinical trial under an IND.255
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Objective: Second allogeneic hematopoietic stem cell transplants
(SCT) and donor lymphocyte infusions (DLI) are used to treat pa-
tients who relapse after initial SCT. DLI can also be used to induce
graft-versus-host disease (GVHD) or promote donor chimerism. To
better understand prognostic factors in this population, we reviewed
our institutional experience with second allogeneic SCT/DLI in
AML patients.
Methods: We performed a retrospective review of AML patients
who received either a second allogeneic SCT or DLI from 1991
through 2009. Progression-free survival (PFS) and overall survival
(OS) were estimated by the Kaplan-Meier method, with day of sec-
ond HSCT/DLI defined as day 0. The COX proportional hazards
method was used to determine the individual impact of the following
factors at second HSCT/DLI on OS: age, sex, interval from initial
transplant, remission status, stem cell graft (CD341) vs. DLI
(CD31), related vs. unrelated donor, GVHD prophylaxis, and
development of acute or chronic GVHD.
Results: 37 AML patients (20 females, 17 males) received a second
HSCT or DLI. Median age was 53 years (range 24-69). 17 (46%)
patients received stem cells, the rest DLI. Twenty two (50%) had re-
lated donors. Median interval from the initial SCT to second SCT/
DLI was 99 days (range 21-1227).
SecondHSCT/DLIwas performed for relapsed/persistent disease
(79%), graft failure (11%), and poor chimerism (11%). Prior to sec-
ond HSCT/DLI, 34% were in complete remission (CR). After sec-
ondHSCT/DLI, 66% of 32 evaluable patients were in CR. 14 of 34
evaluable patients (41%) developed acute GVHD, while 3 (9%) de-
veloped chronic GVHD. Univariate analysis did not reveal any pa-
tient factors that significantly impacted OS. The estimated median
PFS and OS were 65 days (95% CI 38-106) and 103 days (95% CI
56-165), respectively.
For patients retransplanted/given DLI for relapsed AML, OS at
100 days, 1 year, and 2 years were 48%, 23%, and 12% respectively.
As shown in Table 1, better OS was seen in patients who relapsed.
200 days versus\100 days after initial SCT. Of 32 deaths, 10 (31%)
were treatment related, 21 (66%) were disease related, and 1 (3%)
was unknown.
Table 1. Overall survival following second allogeneic SCT/DLI
stratified by time of relapse after first SCT.
Time of relapse after first SCT 100 Day 1 Year 2 Year<100 days 33% 13% 0%
100-200 days 63% 13% 0%
>200 days 88% 50% 25%Conclusion: A second HSCT or DLI offers a chance at remission
for some AML patients who relapse after prior allogeneic SCT.
However treatment related mortality is high. Further exploration
of additional strategies is needed to optimize outcomes of this group
of patients.256
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Overall survival (OS) for acute leukemia in relapse (RL) or induc-
tion failure (IF) treated with HSCT is 16-19% [Duval et al
JCO.2010]. While randomized studies have shown a dose response
relationship, with higher doses of radiation resulting in decreased re-
lapse, this benefit is offset by increased mortality. We report the ini-
tial results of a Phase I trial of 12 patients transplanted between 3/
2008 and 7/2010 in which escalated doses of targeted whole body ra-
diation to marrow bearing areas delivered by Tomotherapy on days
-10 to -6 was added to etoposide 60mg/kg [adj bw] day -5 and
